Q1 EPS Estimate for Soleno Therapeutics Lifted by Analyst

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Equities researchers at HC Wainwright raised their Q1 2025 earnings per share estimates for Soleno Therapeutics in a note issued to investors on Monday, March 31st. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.80) per share for the quarter, up from their previous forecast of ($0.83). HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.76) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at $0.16 EPS, Q3 2026 earnings at $0.37 EPS, Q4 2026 earnings at $1.06 EPS and FY2026 earnings at $1.39 EPS.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.41).

Several other equities research analysts have also recently issued reports on the company. Laidlaw raised their price objective on Soleno Therapeutics from $75.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, March 27th. Guggenheim restated a “buy” rating and issued a $81.00 price target (up previously from $70.00) on shares of Soleno Therapeutics in a report on Friday, March 28th. Lifesci Capital raised shares of Soleno Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 4th. Stifel Nicolaus raised their target price on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the stock a “buy” rating in a research report on Friday, March 28th. Finally, UBS Group set a $105.00 price target on shares of Soleno Therapeutics in a research report on Thursday, March 27th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $99.63.

Soleno Therapeutics Stock Performance

Shares of NASDAQ SLNO opened at $73.67 on Thursday. The firm has a market cap of $3.38 billion, a P/E ratio of -22.19 and a beta of -2.29. Soleno Therapeutics has a 1 year low of $36.61 and a 1 year high of $73.97. The firm’s 50 day moving average price is $50.32 and its 200 day moving average price is $50.50.

Hedge Funds Weigh In On Soleno Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Intech Investment Management LLC acquired a new position in shares of Soleno Therapeutics during the third quarter worth $262,000. Charles Schwab Investment Management Inc. increased its stake in Soleno Therapeutics by 208.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 192,597 shares of the company’s stock worth $9,724,000 after buying an additional 130,080 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Soleno Therapeutics by 6.5% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 52,634 shares of the company’s stock worth $2,657,000 after buying an additional 3,226 shares in the last quarter. FMR LLC boosted its position in Soleno Therapeutics by 6,048,754.5% in the 3rd quarter. FMR LLC now owns 665,374 shares of the company’s stock valued at $33,595,000 after buying an additional 665,363 shares during the last quarter. Finally, MetLife Investment Management LLC grew its stake in shares of Soleno Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 12,772 shares of the company’s stock valued at $645,000 after acquiring an additional 7,196 shares in the last quarter. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Insider Transactions at Soleno Therapeutics

In other news, CFO James H. Mackaness sold 90,622 shares of the company’s stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $69.44, for a total value of $6,292,791.68. Following the completion of the sale, the chief financial officer now owns 105,176 shares of the company’s stock, valued at $7,303,421.44. This represents a 46.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bhatnagar Anish sold 699,095 shares of the stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $67.62, for a total value of $47,272,803.90. Following the completion of the sale, the chief executive officer now owns 577,076 shares of the company’s stock, valued at approximately $39,021,879.12. This trade represents a 54.78 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 945,012 shares of company stock valued at $64,166,842 over the last 90 days. Corporate insiders own 12.30% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.